TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04592120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coalition Check-Up
Description: The Coalition Check-Up identifies and addresses coalition and implementation capacity deficiencies that frequently lead to failure, following recommendations from the audit and feedback literature.
Study: NCT04141059

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligopin
Description: Oligopin capsules composition is :100 mg Oligopin®, 150 mg Maltodextrin, 1.5 mg Mg stearate.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules composition is: 250 mg Maltodextrin and 1.5 mg Mg stearate
Study: NCT04385550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsule
Description: Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK105 injection
Description: AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel injection
Description: Paclitaxel injection 80mg / m² IV on Days 1, 8 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel injection
Description: Docetaxel injection 75mg / m² IV every 3 weeks of each 21-day cycle.
Study: NCT03537547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GeneSight Psychotropic test
Description: GeneSight Psychotropic test, developed by AssureRx Health, is a genetic test that analyses pre-selected pharmacokinetics and pharmacodynamics genes and results in a composite phenotype and interpretive report, addressing both safety and efficacy of psychiatric medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA-approved antidepressant or antipsychotic treatment
Description: Participant is treated with medications included in the GeneSight Psychotropic product.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDA-approved antidepressant or antipsychotic treatment
Description: Participant is treated with medications included in the GeneSight Psychotropic product.
Study: NCT04228926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZKY001 eye drops 0.3g:0.006mg
Description: ZKY001 eye drops of 0.002% continuously for up to 14±2 days after Corneal endothelial transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZKY001 eye drops 0.3g:0.012mg
Description: ZKY001 eye drops of 0.004% continuously for up to 14±2 days after Corneal endothelial transplantation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZKY001 simulated eye drops
Description: ZKY001 simulated eye drops continuously for up to 14±2 days after Corneal endothelial transplantation
Study: NCT00151632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil is administered at a dose of 1,5 g x 2 / day for the 6 first weeks, then 1g x 2 / day until M12.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: In arm 1: Tacrolimus is administered at half recommended dose: 0,040 mg/Kg x 2 , in order to maintain plasma levels between 6 and 10 ng/ml for the 6 first weeks, between 5 and 8 ng/ml from week 7 to M6 and between 4 and 6 ng/ml between M6 and M12.~In arm 2: Tacrolimus is administered at the recommended dose: 0,075 mg/Kg x 2 , in order to maintain plasma levels between 12 and 20 ng/ml for the 6 first weeks, between 10 and 15 ng/ml from week 7 to week 12, between 8 and 12 ng/ml between M4 and M6 and between 6 and 10 ng/ml between M6 and M12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: In arm 1: Tacrolimus is administered at half recommended dose: 0,040 mg/Kg x 2 , in order to maintain plasma levels between 6 and 10 ng/ml for the 6 first weeks, between 5 and 8 ng/ml from week 7 to M6 and between 4 and 6 ng/ml between M6 and M12.~In arm 2: Tacrolimus is administered at the recommended dose: 0,075 mg/Kg x 2 , in order to maintain plasma levels between 12 and 20 ng/ml for the 6 first weeks, between 10 and 15 ng/ml from week 7 to week 12, between 8 and 12 ng/ml between M4 and M6 and between 6 and 10 ng/ml between M6 and M12.
Study: NCT00738894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Septal Occluder Device
Description: PFO closure with study septal occluder device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet Medical Therapy
Description: Investigator's choice of one of three regimen options specified in protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet Medical Therapy
Description: Investigator's choice of one of three regimen options specified in protocol
Study: NCT03901482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Description: Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Description: Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo for STS101
Study: NCT01382277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 20 mg per day for 76 weeks
Study: NCT03878992

Intervention type: DRUG
Group type: OTHER
Intervention: Genotropin miniquick 0.5 mg, injection
Description: GH will be given as an injection. Muscle biopsy will be obtained from m. vests laterals of the dominant leg. Fat biopsies will be obtained from subcutaneous abdominal fat. Tracers will be given as a bolus followed by continuous infusion for 6 hours. For palmitate tracer the infusion will be for only 1,5 hours followed by a one hour break and then another 1 hour infusion. Blood tests will be drawn from a venous catheter placed on the dorsal side of the hand.
Study: NCT02149953

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycine Intake
Description: Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
Study: NCT03849677

Intervention type: OTHER
Intervention: Endothelial function and inflammation
Description: Analysis of endothelial function, oxidative stress

Intervention type: OTHER
Intervention: Endothelial function and inflammation
Description: Analysis of endothelial function, oxidative stress
Study: NCT03857997

Intervention type: BIOLOGICAL
Intervention: Patient blood sampling
Description: sequencing by WGS and RNA-seq

Intervention type: BIOLOGICAL
Intervention: Parents blood sampling
Description: sequencing by WGS
Study: NCT01373151

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BMS-945429 Placebo
Description: Injection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous, 25 mg, Every 4 weeks, Day 1 - Week 24 only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BMS-945429
Description: Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Tablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablets, Oral, 15 mg, Weekly, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablets, Oral, 15 mg, Weekly, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablets, Oral, 15 mg, Weekly, 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Tablets, Oral, 15 mg, Weekly, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Placebo
Description: Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Placebo
Description: Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab Placebo
Description: Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
Study: NCT03309449

Intervention type: DEVICE
Group type: OTHER
Intervention: Intranasal mucosal atomization device
Description: Intranasal atomizer administration of simulated naloxone

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal spray
Description: Nasal spray administration of simulated naloxone
Study: NCT02837822

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulator
Description: Spinal cord stimulator is a reversible and minimally invasive neuromodulation device used for the treatment of various diseases related to chronic pain, including CRPS and FBSS. Briefly, this technology uses electrical pulses to generate action potentials in nerve cells that induce paresthesias (buzzing or tingling sensations) in the affected limb and can relieve pain.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulator
Description: Spinal cord stimulator is a reversible and minimally invasive neuromodulation device used for the treatment of various diseases related to chronic pain, including CRPS and FBSS. Briefly, this technology uses electrical pulses to generate action potentials in nerve cells that induce paresthesias (buzzing or tingling sensations) in the affected limb and can relieve pain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of a spinal cord stimulator
Description: The electrical pulses are induced by one or more electrodes surgically implanted into the epidural space. These electrodes are usually placed under the skin in the abdomen or upper buttock.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of a spinal cord stimulator
Description: The electrical pulses are induced by one or more electrodes surgically implanted into the epidural space. These electrodes are usually placed under the skin in the abdomen or upper buttock.
Study: NCT00665041

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Quinagolide
Description: • Quinagolide 200 μg/day (dose titration from 50 μg/day to 100 μg/day to 200 μg/day), oral. Quinagolida tablets, 50 mcg.~placebo, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinagolide
Description: • Quinagolide 200 μg/day (dose titration from 50 μg/day to 100 μg/day to 200 μg/day), oral. Quinagolida tablets, 50 mcg.~placebo, oral.
Study: NCT02565420

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients will be administered normal saline for intraoperative fluid management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's solution
Description: Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
Study: NCT04371809

Intervention type: OTHER
Intervention: DNA methylome
Description: Epigenomics tools combined with bioinformatic analysis to find and correlate putative useful clinical biomarkers with clinical features

Intervention type: OTHER
Intervention: DNA methylome
Description: Epigenomics tools combined with bioinformatic analysis to find and correlate putative useful clinical biomarkers with clinical features

Intervention type: OTHER
Intervention: DNA methylome
Description: Epigenomics tools combined with bioinformatic analysis to find and correlate putative useful clinical biomarkers with clinical features

Intervention type: OTHER
Intervention: DNA methylome
Description: Epigenomics tools combined with bioinformatic analysis to find and correlate putative useful clinical biomarkers with clinical features
Study: NCT02984982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelets
Description: Pharmaceutical form: tablet or capsule~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelets
Description: Pharmaceutical form: tablet or capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Description: Pharmaceutical form: tablet or capsule~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulants
Description: Pharmaceutical form: tablet or capsule~Route of administration: oral
Study: NCT02481050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes biweekly on Day 1 and Day 15 of each 28-day cycle.
Study: NCT04478617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Vaginal
Description: Vaginal metronidazole 0.75% (MetroGel or Vandazole) will be inserted per vagina days 1 through 5 prior to date of surgery.
Study: NCT03398473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Hospira SDV
Description: Epoetin Hospira Single Dose Vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Hospira MDV
Description: Epoetin Hospira Multi-Dose Vial
Study: NCT00185315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ventavis (Iloprost, BAYQ6256)
Description: Inhaled iloprost
Study: NCT00683423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-741672
Description: Tablets, Oral, 100 mg, once daily, 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, 3 weeks treatment period, 2 weeks washout, and 2 weeks follow-up
Study: NCT04632004

Intervention type: OTHER
Group type: OTHER
Intervention: Invitation to participate
Description: Patients, visitors, and staff members of the University Medical Center Goettingen are invited to participate within our survey study. Study participation has no effect on any medical treatment.
Study: NCT04997603

Intervention type: OTHER
Group type: OTHER
Intervention: Accelerometer
Description: Fitbit brand

Intervention type: OTHER
Group type: OTHER
Intervention: Accelerometer
Description: Fitbit brand
Study: NCT04051541

Intervention type: OTHER
Group type: OTHER
Intervention: Agitated saline push
Description: Push of agitated saline to simulate adenosine used for supraventricular tachycardia
Study: NCT04036487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Anesthesia is maintained by desflurane in an oxygen air mixture of 60/40%. If inadequate depth of anesthesia is observed, the end-expiratory concentration of desflurane would be increased.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthesia is maintained by propofol 100-200 μg/kg/min. If inadequate depth of anesthesia is observed, the rate of propofol infusion would be increased.
Study: NCT01229878

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (Vitamin D)
Description: 50,000 units of cholecalciferol or a placebo pill administered once a week for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol (Vitamin D)
Description: 50,000 units of cholecalciferol or a placebo pill administered once a week for 6 months
Study: NCT01155817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: 200, 400, 800, oral
Study: NCT00452439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actonel (Risedronate)
Description: 35 mg (pill) by mouth weekly

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: 500 mg by mouth twice a day for a total of 24 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: 500 mg by mouth twice a day for a total of 24 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 400 IU by mouth twice a day for a total of 24 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: 400 IU by mouth twice a day for a total of 24 months.
Study: NCT03031340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: On the day of the surgery, 1hour + 15 minutes before the surgery starts, the subject will receive either 300mg of pregabalin or a similarly packaged placebo. On post operative day one, 150 mg of pregabalin or placebo will be given in two doses 12hrs apart.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01103323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: 160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care (BSC)
Description: BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
Study: NCT00086190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: Paroxetine 10 mg tablets or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the paroxetine or matching placebo will be increased to 20 mg, followed by a 10 mg increase every two weeks (if tolerated). Dosage for this study will not exceed 40 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine
Description: Venlafaxine XR 37.5 mg capsules or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the venlafaxine XR capsules or matching placebo will be increased to 75 mg followed by 75 mg increments every 2 weeks (if tolerated). Dosage for this study will not exceed 225 mg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study: NCT01458067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2636771
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2636771
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2636771
Description: Oral capsules
Study: NCT02778217

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Culture media renwal
Study: NCT03019484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding support
Description: Self-efficacy
Study: NCT01265498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: obeticholic acid
Description: 25 mg daily for 72 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule, 25 mg daily for 72 weeks
Study: NCT02903446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy
Study: NCT03902613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Participant will have an open label trial of lurasidone for eight weeks.
Study: NCT00101244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ispinesib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04621799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Description: The intra-annular delivery of non-autologous fibrin into the annulus
Study: NCT01542450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
Study: NCT01373151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Placebo
Description: Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Placebo
Description: Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
Study: NCT01542450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin NPH
Description: Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days